Registered outcomes12

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

1 to 12 of 12

List	Outcome	Time frame	Description
Primary	primary efficacy outcome	the initial 24 hours after study drug administration;	Total blood loss within 24 hours of trial drug administration will be our primary efficacy outcome.
Primary	primary safety outcome	the initial 7 postoperative days after study drug administration	the primary safety outcome will be the incidence of a collapsed (one or more) composite of thrombotic events during the initial 7 postoperative days, including non-hemorrhagic strokes, myocardial injury after non-cardiac surgery (MINS), pulmonary embolism, hepatic artery embolism, portal vein thrombosis, bowel infarction, peripheral arterial thrombosis, symptomatic proximal venous thromboembolism.
Secondary	Estimated blood loss based on physician's assessment within the initial 24 hours of trial drug administration.	within the initial 24 hours after trial drug administration	Estimated loss will be recorded by the attending anesthesiologist who collect blood loss at the end of surgery by adding the blood volume recovered in the suction canisters, and the sponges (by weighing surgical sponges before and after surgical use), and then subtracted the irrigation fluid, lymph, bile, serum, ascites, urine, and other fluids solution volumes, and finally add the postoperative drainage volume in the intensive care unit.
Secondary	Postoperative abdominal tube drainage volume during the initial 72 hours	within the initial 72 hours after study drug administration	The cumulative volume of fluid collected from the intra-abdominal drainage tube(s) placed during liver transplantation. Drainage will be measured and recorded at regular intervals for the first 72 hours after study drug administration. The total amount (in milliliters) over this 72-hour period will be recorded.
Secondary	Units of RBC transfused within 72 hours.	within the initial 72 hours after study drug administration	RBC transfusion will be based on clinical need, but generally initiated when intraoperative hemoglobin is less than 70 g/L\[40\].
Other	The incidence of early allograft dysfunction (EAD) or primary nonfunction (PNF) within the initial 7 postoperative days.	within the initial 7 postoperative days after study drug administration	EAD is defined according to Olthoff's criteria as one of the following: (a) bilirubin ≥ 10 mg/dL on day 7; or (b) INR ≥ 1.6 on day 7; or (c) AST/ ALT \> 2000 IU/L within first 7 days. PNF is defined as graft loss, re-transplantation, or patient death due to graft non-function in first 30 days (excluding non-function secondary to hepatic artery thrombosis, biliary complications, or recurrent hepatic disease).
Other	Acute Kidney Injury (AKI) stage within the initial 7 postoperative days as defined by KDIGO	within the initial 7 postoperative days after study drug administration	The stages of Acute Kidney Injury (AKI) within first 7 days which is defined according to KDIGO (Kidney Disease Improving Global Outcomes criteria\[33\]: Stage 1 (a) increase in SCr by 0.3 mg/dl within any 48-hour window; or (b) increase in SCr to 1.5 times of baseline within the past 7 days; or (c) urine output less than 0.5 ml/kg/h for 6 hours. Stage 2 (a) increase in SCr to 2.0 times of baseline within the past 7 days; (b) urine output less than 0.5 ml/kg/hour for more than 12 hours.
Other	Surgical complications and related Clavien Dindo classification within 30 days of surgery	30 days after study drug administration
Other	Total hours of mechanical ventilation after surgery	30 days after study drug administration
Other	Total hours in an ICU after surgery	30 days after study drug administration
Other	Duration of postoperative hospitalizataion	30 days after study drug administration
Other	All-cause mortality within 30 days after surgery	30 days after study drug administration	determined by medical records and phone calls

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT07157631/registered

API reference For AI assistants